Table 2 |
||||
|
Baseline clinical variables and B-cell subsets in responders and non-responders, as determined by univariate logistic regression |
||||
|
Clinical variable or B-cell subset |
Responders |
Non-responders |
OR (95% CI) |
P value |
|
|
||||
|
Age in years, median (interquartile range) |
62.9 (58.2-67.7) |
60.6 (49.7-71.4) |
0.99 (0.92-1.05) |
0.647 |
|
sDMARD use, median (interquartile range) |
2.5 (2.1-2.8) |
2.4 (1.5-3.3) |
0.84 (0.33-2.14) |
0.956 |
|
Prior anti-TNF use, median (interquartile range) |
1.1 (0.8-1.4) |
1.1 (0.3-2.0) |
1.02 (0.37-2.80) |
0.978 |
|
ESRa, median (interquartile range) |
6.1 (5.4-6.8) |
5.0 (2.9-7.2) |
0.74 (0.47-1.17) |
0.202 |
|
Rheumatoid factor, number (percentage) |
||||
|
Positive |
27 (90.0) |
7 (100.0) |
1.91 (0.43-8.32) |
0.389b |
|
Negative |
3 (10.0) |
0 (0.0) |
||
|
B-cell subset, median (interquartile range) |
||||
|
Naïve cellsc |
8.9 (8.6-9.3) |
9.2 (8.6-9.8) |
1.51 (0.56-4.11) |
0.416 |
|
Post-switch memoryc |
7.4 (7.1-7.6) |
7.9 (7.4-8.5) |
3.91 (0.93-16.45) |
0.063 |
|
Plasmablastsd |
3.8 (3.3-4.4) |
5.2 (3.8-6.6) |
2.22 (1.04-4.74) |
0.040 |
|
B-cell depletion, number (percentage) |
||||
|
Complete |
2 (6.7) |
1 (14.3) |
2.33 (0.18-30.10) |
0.516 |
|
Incomplete |
28 (93.3) |
6 (85.7) |
||
|
|
||||
|
aSquare root values; bcalculated from contingency table, Pearson-Mantel-Haenszel P value; cnatural log (absolute number of cells); dnatural log (absolute number of cells + 1). anti-TNF, anti-tumor necrosis factor; CI, confidence interval; ESR, erythrocyte sedimentation rate; OR, odds ratio; sDMARD, synthetic disease-modifying anti-rheumatic drug. |
||||
|
Brezinschek et al. Arthritis Research & Therapy 2012 14:R161 doi:10.1186/ar3901 |
||||
